Dr. Reddy’s Laboratories Announces Tax Deduction on Dividend Payouts

Dr Reddy’s Laboratories ( (RDY) ) just unveiled an announcement.

On June 20, 2025, Dr. Reddy’s Laboratories announced via a newspaper advertisement the deduction of tax at source on dividend payouts to its shareholders. This information was published in Business Standard and Nava Telangana and communicated to shareholders via email. The announcement is part of the company’s compliance with SEBI regulations, ensuring transparency and adherence to disclosure requirements, which may impact shareholder returns and the company’s financial reporting.

The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories’ strong financial performance is the most significant factor, underscored by consistent revenue growth and profitability. Technical analysis supports a favorable stock trend, although valuation is fair with modest income potential. The absence of earnings call and corporate events data did not impact the overall score.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical industry, based in Hyderabad, India. The company is known for its production of generic medications, active pharmaceutical ingredients, and proprietary products, focusing on delivering affordable and innovative medicines to patients worldwide.

Average Trading Volume: 2,114,557

Technical Sentiment Signal: Strong Buy

Current Market Cap: $12.64B

Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.